Additionally, the unique tumor specificity of [18F]FAMT structure presents opportunities for theranostic applications, particularly in the development of LAT1-targeted radiopharmaceuticals for targeted alpha therapy (TAT). This evidence concerns the gene SLC7A5 and neoplasm.